[go: up one dir, main page]

WO1991011525A3 - Vaccins - Google Patents

Vaccins Download PDF

Info

Publication number
WO1991011525A3
WO1991011525A3 PCT/GB1991/000107 GB9100107W WO9111525A3 WO 1991011525 A3 WO1991011525 A3 WO 1991011525A3 GB 9100107 W GB9100107 W GB 9100107W WO 9111525 A3 WO9111525 A3 WO 9111525A3
Authority
WO
WIPO (PCT)
Prior art keywords
promoter
gene
recombinant virus
region
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1991/000107
Other languages
English (en)
Other versions
WO1991011525A2 (fr
Inventor
Norman Spibey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Original Assignee
University of Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow filed Critical University of Glasgow
Priority to CA002074502A priority Critical patent/CA2074502C/fr
Priority to EP91903143A priority patent/EP0512017B1/fr
Priority to DE69126606T priority patent/DE69126606T2/de
Priority to KR1019920701760A priority patent/KR920703831A/ko
Publication of WO1991011525A2 publication Critical patent/WO1991011525A2/fr
Publication of WO1991011525A3 publication Critical patent/WO1991011525A3/fr
Anticipated expiration legal-status Critical
Priority to GR970401882T priority patent/GR3024242T3/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention se rapporte à un adénovirus recombinant agissant comme vecteur pour un gène producteur d'antigènes (tel qu'un gène de glycoprotéine rabique) et qui comprend une souche de CAV-2 modifiée de façon à contenir la séquence des gènes promoteurs à l'intérieur de la région allant du site SmaI proche de l'extrémité de la répétition terminale inversée jusqu'au promoteur pour la région précoce 4 (E4). Pour faciliter la réplication, le virus recombinant est transfecté dans une lignée cellulaire exprimant des protéines Ela. Ce virus recombinant est utilisé pour la production d'un vaccin correspondant.
PCT/GB1991/000107 1990-01-25 1991-01-25 Vaccins Ceased WO1991011525A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002074502A CA2074502C (fr) 1990-01-25 1991-01-25 Vaccins
EP91903143A EP0512017B1 (fr) 1990-01-25 1991-01-25 Vaccins
DE69126606T DE69126606T2 (de) 1990-01-25 1991-01-25 Vakzine
KR1019920701760A KR920703831A (ko) 1990-01-25 1991-01-25 백신(vaccines)
GR970401882T GR3024242T3 (en) 1990-01-25 1997-07-25 Vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9001766.6 1990-01-25
GB909001766A GB9001766D0 (en) 1990-01-25 1990-01-25 Vaccines

Publications (2)

Publication Number Publication Date
WO1991011525A2 WO1991011525A2 (fr) 1991-08-08
WO1991011525A3 true WO1991011525A3 (fr) 1991-09-05

Family

ID=10669925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1991/000107 Ceased WO1991011525A2 (fr) 1990-01-25 1991-01-25 Vaccins

Country Status (14)

Country Link
EP (1) EP0512017B1 (fr)
JP (1) JP3159446B2 (fr)
KR (1) KR920703831A (fr)
AU (1) AU641211B2 (fr)
CA (1) CA2074502C (fr)
DE (1) DE69126606T2 (fr)
DK (1) DK0512017T3 (fr)
ES (1) ES2103001T3 (fr)
GB (1) GB9001766D0 (fr)
GR (1) GR3024242T3 (fr)
HU (1) HUT65368A (fr)
NZ (1) NZ236887A (fr)
WO (1) WO1991011525A2 (fr)
ZA (1) ZA91534B (fr)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE256746T1 (de) * 1991-04-25 2004-01-15 Akzo Nobel Nv Subeinheits-impfstoff gegen hundecoronavirus
US6099831A (en) * 1992-09-25 2000-08-08 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
FR2681786A1 (fr) * 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
US6743623B2 (en) 1991-09-27 2004-06-01 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US5820868A (en) * 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
DE69740033D1 (de) * 1996-07-03 2010-12-09 Merial Inc Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
EP0998576B1 (fr) 1997-06-23 2007-10-31 The University of Saskatchewan Méthode pour la production d'un vecteur récombinant de l'adenovirus bovin
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6451319B1 (en) 1999-04-09 2002-09-17 Schering-Plough Veterinary Corporation Recombinant and mutant adenoviruses
WO2001092547A2 (fr) 2000-05-31 2001-12-06 University Of Saskatchewan Adenovirus bovin modifie avec modification du tropisme
US6916635B2 (en) 2000-10-02 2005-07-12 The Research Foundation Of State University Of New York Hybrid adenovirus/adeno-associated virus vectors and methods of use thereof
FR2845395B1 (fr) * 2002-10-08 2008-05-30 Agronomique Inst Nat Rech Vecteurs adenoviraux recombinants et leurs applications
EP1606419A1 (fr) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systemes et procedes pour accroitre la production de proteines et de lait chez des bovins laitiers
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US20050214316A1 (en) 2003-11-13 2005-09-29 Brown Thomas P Methods of characterizing infectious bursal disease virus
WO2005112544A2 (fr) 2004-02-19 2005-12-01 The Governors Of The University Of Alberta Polymorphismes du promoteur de la leptine et utilisations correspondantes
ATE461710T1 (de) 2005-04-25 2010-04-15 Merial Ltd Nipah-virus-impfstoffe
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP3536704B1 (fr) 2005-11-14 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Thérapie génique pour traiter l'insuffisance rénale
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
CN102428099B (zh) 2009-04-03 2016-03-16 梅里亚有限公司 运载新城疫病毒的禽疫苗
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
EP4014989A1 (fr) 2010-08-31 2022-06-22 Boehringer Ingelheim Animal Health USA Inc. Vaccins du virus de l'herpès vectorisé par le virus de la maladie de newcastle
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2012090073A2 (fr) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Procédés et compositions pour prédire la sensibilité à la chimiothérapie
AU2012240246A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
AU2012240240A1 (en) 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
WO2012145509A2 (fr) 2011-04-19 2012-10-26 The Research Foundation Of State University Of New York Séquences rep de virus adéno-associé, vecteurs, et virus
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
US10081658B2 (en) 2011-04-25 2018-09-25 Advanced Bioscience Laboratories, Inc. Truncated HIV envelope proteins (ENV), methods and compositions related thereto
EP2714077B1 (fr) 2011-06-01 2018-02-28 Merial, Inc. Administration sans aiguille de vaccins contre le vsrrp
HUE035774T2 (en) 2011-08-12 2018-05-28 Merial Inc Biological substances, in particular vaccines, preserved by vacuum
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (fr) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Antigènes de poil de streptococcus suis
WO2013093629A2 (fr) 2011-12-20 2013-06-27 Netherlands Cancer Institute Vaccins modulaires, procédés et compositions qui y sont liés
WO2013138776A1 (fr) 2012-03-16 2013-09-19 Merial Limited Nouveaux procédés pour fournir une immunité de protection à long terme contre la rage chez des animaux, basés sur l'administration d'un flavivirus défectueux en termes de réplication, exprimant la rage g
ES2689878T3 (es) 2013-02-21 2018-11-16 Boehringer Ingelheim Vetmedica Gmbh Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento
US9556419B2 (en) 2013-03-12 2017-01-31 Merial Inc. Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
CN107073101B (zh) 2014-04-03 2020-10-27 勃林格殷格翰动物保健美国有限公司 猪流行性腹泻病毒疫苗
CA2966191A1 (fr) 2014-11-03 2016-05-12 Merial, Inc. Procedes d'utilisation de formulations de vaccin par micro-aiguilles pour eliciter une immunite de protection contre le virus de la rage chez les animaux
NZ738957A (en) 2015-06-23 2019-09-27 Boehringer Ingelheim Animal Health Usa Inc Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof
PL3344289T3 (pl) 2015-08-31 2021-01-11 Boehringer Ingelheim Vetmedica Gmbh Szczepionki Pestiwirusowe na drżenia wrodzone
AU2016323106A1 (en) 2015-09-16 2018-03-29 Boehringer Ingelheim Animal Health USA Inc. Salmonella Choleraesuis-Salmonella Typhimurium vaccines
WO2018057441A1 (fr) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh Vecteurs d'adénovirus canin
AU2017329672B2 (en) 2016-09-20 2023-07-27 Boehringer Ingelheim Vetmedica Gmbh New promoters
MX2019003161A (es) 2016-09-20 2019-05-27 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de insercion orf70 de ehv.
EA201990717A1 (ru) 2016-09-20 2019-10-31 Новая вакцина против гриппа свиней
UA127859C2 (uk) 2016-11-03 2024-01-31 Бьорінгер Інгельхайм Ветмедіка Гмбх Вакцина проти свинячого парвовірусу
FI3534939T3 (fi) 2016-11-03 2023-05-15 Boehringer Ingelheim Vetmedica Gmbh Rokote sian parvovirusta ja sian hedelmättömyyttä ja respiratorista oireyhtymää aiheuttamaa virusta vastaan ja menetelmän sen valmistamiseksi
CA3046684A1 (fr) 2017-01-30 2018-08-02 Boehringer Ingelheim Animal Health USA Inc. Vaccins contre le coronavirus porcin
EP3651797A1 (fr) 2017-07-12 2020-05-20 Boehringer Ingelheim Animal Health USA Inc. Compositions immunogènes à base de sénécavirus de type a et procédés correspondants
AR113124A1 (es) 2017-09-23 2020-01-29 Boehringer Ingelheim Vetmedica Gmbh Sistema de expresión de paramyxoviridae
WO2019092027A1 (fr) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Compositions immunogènes à base de sapelovirus et leurs utilisations
KR20200124713A (ko) 2018-02-23 2020-11-03 베링거잉겔하임베트메디카게엠베하 외인성 펠라인 파라믹소바이러스 유전자를 발현하는 재조합 바이러스 벡터 시스템 및 이로부터 제조된 백신
WO2019179998A1 (fr) 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica Gmbh Nouveaux ehv avec ul18 et/ou ul8 inactivés
US11596681B2 (en) 2018-03-19 2023-03-07 Boehringer Ingelheim Vetmedica Gmbh EHV insertion site UL43
CA3091982A1 (fr) 2018-03-26 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Procede de production d'une composition immunogene
CN112867506B (zh) 2018-09-20 2025-08-05 勃林格殷格翰动物保健有限公司 抗猪流行性腹泻的鼻内载体疫苗
KR102879825B1 (ko) 2018-09-20 2025-11-03 베링거잉겔하임베트메디카게엠베하 변형된 pedv 스파이크 단백질
JP2023513135A (ja) 2020-02-06 2023-03-30 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 抗ラブドウイルス抗体を検出するのに有用なポリペプチド
AU2021356630A1 (en) 2020-10-05 2023-06-08 Boehringer Ingelheim Vetmedica Gmbh Fusion protein useful for vaccination against rotavirus
WO2022076977A1 (fr) 2020-10-05 2022-04-14 Boehringer Ingelheim Animal Health USA Inc. Protéine de fusion comprenant une protéine capsidique de circovirus, et particules pseudo-virales chimériques composées de cette dernière
JP2025511739A (ja) 2022-04-05 2025-04-16 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ロタウイルスに対するワクチン接種のために有用な免疫原性組成物
WO2024243578A1 (fr) 2023-05-25 2024-11-28 Dispatch Biotherapeutics, Inc. Antigènes synthétiques de cancers en tant que cibles pour le traitement de cancers
WO2025171383A2 (fr) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Antigènes du cancer modifiés et procédés et utilisations associés
WO2025171388A1 (fr) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Antigènes du cancer modifiés avec des domaines modifiés et procédés et utilisations associés

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181117A2 (fr) * 1984-11-01 1986-05-14 American Home Products Corporation Vaccins oraux

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181117A2 (fr) * 1984-11-01 1986-05-14 American Home Products Corporation Vaccins oraux

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Gene, volume 55, 1987, Elsevier Science B.V., M. Shinagawa et al.: "Phylogenetic relationships between adenoviruses as inferred from nucleotide sequences of inverted terminal repeats", page 85 *
J. Gen. Virol., Volume 70, 1989, SGM, N. Spibey et al.: "Molecular cloning and restriction endonuclease mapping oftwo strains of canine adenovirus type 2", pages 165-172 *
Journal of Virology, volume 54, no. 3, June 1985, American Society for Microbiology, I. Saito et al.: "Construction of nondefective adenovirus type 5 bearing a 2.8-kilobase hepatitis B virus DNA near the right end of its genome", pages 711-719 *
Technological Advances in Vaccine Development, 1988, Alan R. Liss, Inc., F.L. Graham et al.: "Cloning and expression of glycoprotein genes in human adenovirus vectors 1", pages 243-253 *
Trends in Biotechnology, volume 8, no. 4, April 1990, Elsevier Science Publishers Ltd, (Cambridge, GB), F.L. Graham: "Adenoviruses as expression vectors and recombinant vaccines", pages 85-87 *
Virus Research, volume 14, 1989, Elsevier Science Publishers B.V., N. Spibey et al.: "Identification and nucleotide sequence of the early region 1 from canine adenovirus types 1 and 2" pages 241-256 *

Also Published As

Publication number Publication date
AU7075691A (en) 1991-08-21
ES2103001T3 (es) 1997-08-16
CA2074502A1 (fr) 1991-07-26
KR920703831A (ko) 1992-12-18
CA2074502C (fr) 2001-07-17
NZ236887A (en) 1992-04-28
GB9001766D0 (en) 1990-03-28
HUT65368A (en) 1994-05-02
JP3159446B2 (ja) 2001-04-23
EP0512017B1 (fr) 1997-06-18
DK0512017T3 (da) 1998-01-19
AU641211B2 (en) 1993-09-16
DE69126606T2 (de) 1998-01-08
ZA91534B (en) 1991-11-27
JPH05505306A (ja) 1993-08-12
WO1991011525A2 (fr) 1991-08-08
DE69126606D1 (de) 1997-07-24
HU9202436D0 (en) 1992-12-28
EP0512017A1 (fr) 1992-11-11
GR3024242T3 (en) 1997-10-31

Similar Documents

Publication Publication Date Title
WO1991011525A3 (fr) Vaccins
DK0738327T3 (da) Vært-vektorsystem til anvendelse ved genterapi
EP0596979A4 (en) Recombinant plant viral nucleic acids.
DE3851399D1 (de) Transientes Expressionssystem zur Herstellung von rekombinantem Protein.
EP0766569A4 (fr) Capsides de virus adeno-associe utilises comme vecteurs pour le transfert moleculaire
EE05138B1 (et) Rekombinantne MVA viirus ja selle kasutamine, isoleeritud eukarootne rakk, meetod rekombinantse HIV Nef-proteiini valmistamiseks ning vaktsiin
IE821428L (en) Foot and mouth disease vaccine
AU7335296A (en) Recombinant sendai virus
EP1605052A3 (fr) Procédé de production de vaccins antigrippaux polyvalents composés d'hemagglutinine
EP0979101A4 (fr) ADENOVIRUS CANIN DE RECOMBINAISON (ACR) CONTENANT DE l'ADN EXOGENE
ES2000278A6 (es) Procedimiento para preparar una proteina de fusion y para preparar una proteina eucariotica.
DE68922917D1 (de) KEX2-Endoprotease und Verfahren zu ihrer Herstellung.
NZ240318A (en) Preparation of proteins using a baculovirus expression system
AU5572786A (en) Expression of immunologically reactive aids viral protein
DK564789D0 (da) Fremgangsmaade til ekspression af et eukaryot gen
KR970705408A (ko) 헤모필루스 부착 및 침투 단백질(haemophilus adherence and penetration proteins)
AU605155B2 (en) A structural phosphoprotein (PP 15) of human cytomegalovirus, and the preparation and use thereof
EP0112012A3 (fr) Molécules recombinantes d'ADN
EP0460217A4 (en) Cdna of orsv gene
PT1275726E (pt) Método para produzir vacinas multivalentes de hemaglutinina de influenza
SU1380209A1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК PUR 291-HAV 22, КОДИРУЮЩАЯ СИНТЕЗ ГИБРИДНОГО ПОЛИПЕПТИДА АНТИГЕННЫХ ДЕТЕРМИНАНТ ВИРУСА ГЕПАТИТА А С β -ГАЛАКТОЗИДАЗОЙ

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA GB HU JP KR US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA GB HU JP KR US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991903143

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2074502

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991903143

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991903143

Country of ref document: EP